University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial Search: "GASTROINTESTINAL"



Treatment trials which apply specifically to your search:


0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-12-4

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Multi-Center, Extension Study of NKTR-102 in Subjects Previously Enrolled in NKTR-102 Studies.

Treatment:
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-4

Trial Leaders:
Heinz Josef Lenz

A Phase I, Open-Label, Multiple-Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-13-8

Trial Leaders:
Heinz Josef Lenz

A Phase Ib/II Clinical Study of BBI608 Administered with Paclitaxel in Adult Patients with Advanced Malignancies

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-11

Trial Leaders:
Anthony El-Khoueiry

A Phase 1, Open-Label, Dose Escalation Study of Pf-04518600 as a Single Agent and In Combination with PF-05082566 In Patients with Selected Locally Advanced or Metastatic Carcinomas

Treatment:
Chemotherapy: Systemic

0C-14-2

Trial Leaders:
David Quinn

An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (Egfr, Her2, Her3) Mutations or EGFR Gene Amplification

Treatment:
Chemotherapy: Systemic

0C-14-6

Trial Leaders:
David Quinn

A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

Treatment:
Immunotherapy

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0R-14-2

Trial Leaders:
Eric Chang

Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation prior to or following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)

Treatment:
Other

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

0S-10-3

Trial Leaders:
Tanya Dorff

A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy.

Treatment:
Other

0S-13-4

Trial Leaders:
James Hu

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) vs. Bleomycin, Etoposide and Cisplatin (BEP) for Patients with Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Treatment:
Chemotherapy: Systemic

0S-14-6

Trial Leaders:
Kevin Kelly

Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects with Refractory or Relapsed Lymphoma or Multiple Myeloma

Treatment:
Chemotherapy: Systemic

0S-14-9

Trial Leaders:
Heinz Josef Lenz

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination with Nivolumab in Select Advanced Cancers

Treatment:
(No treatments specified)

0S-15-1

Trial Leaders:
Heinz Josef Lenz

A Multi-Center Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with MEDI4736, in Subjects with Relapsed or Refractory Solid Tumors

Treatment:
Chemotherapy: Systemic

0S-15-5

Trial Leaders:
Anthony El-Khoueiry

A Pilot Multi-Arm Study of sEphB4-HSA In Combination with Different Chemotherapy Regimens in Patients with Specific Advanced or Metastatic Solid Tumors

Treatment:
Chemotherapy: Systemic

13NHL-14-3

Trial Leaders:
Anil Tulpule

Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of lenalidomide (CC-5013) plus R-Chop Chemotherapy (R2-Chop) versus Placebo plus R-Chop Chemotherapy in Subjects with Previously Untreated Activated B-Cell Type Diffuse Large B-Cell Lymphoma

Treatment:
Chemotherapy: Systemic

16M-13-2

Trial Leaders:
Ann Mohrbacher

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone versus Bortezomib and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Treatment:
Chemotherapy: Systemic

16M-15-2

Trial Leaders:
Kevin Kelly

A Phase 1b Study of REOLYSIN® combined with Standard Doses of Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Treatment:
Chemotherapy: Systemic

1B-12-1

Trial Leaders:
Christina M. Dieli-Conwright

Combined Exercise Program for Early Breast Cancer Survivors.

Treatment:
(No treatments specified)

1B-12-10

Trial Leaders:
Darcy Spicer

Phase II Trial of Metronomic Capecitabine and Cyclophosphamide with Lapatinib and Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen.

Treatment:
Chemotherapy: Systemic
Immunomodulator

1B-13-1

Trial Leaders:
Christy Russell

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer

Treatment:
Chemotherapy: Systemic

1B-13-10

Trial Leaders:
Darcy Spicer

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer. (The “METRIC” Study)

Treatment:
Chemotherapy: Systemic

1B-13-11

Trial Leaders:
Christy Russell

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician’s Choice In Previously-Treated, HER2 Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Treatment:
Chemotherapy: Systemic

1B-14-5

Trial Leaders:
Christina M. Dieli-Conwright

High-intensity Interval training (HIT) for Breast Cancer Patients during Trastuzumab Use

Treatment:
Other

1B-14-7

Trial Leaders:
Heather R. Macdonald

Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women

Treatment:
Other

2N-13-4

Trial Leaders:
Barbara Gitlitz

A Randomized Phase II Trial of Cytotoxic Chemotherapy with or without Epigenetic Priming in Patients with Advanced Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Systemic

2N-15-2

Trial Leaders:
Jorge Nieva

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Treatment:
Other

2N-15-4

Trial Leaders:
Jorge Nieva

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer

Treatment:
Biological Response Modifier

2N-15-5

Trial Leaders:
Barbara Gitlitz

A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges

Treatment:
Chemotherapy: Local

2N-15-6

Trial Leaders:
Barbara Gitlitz

Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer

Treatment:
Chemotherapy: Local

2N-15-7

Trial Leaders:
Barbara Gitlitz

A Phase 2 Study of TH-4000 in Patients with EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Treatment:
Biological Response Modifier

3BD-14-1

Trial Leaders:
Jaques Van Dam

Multicenter, open-label, randomized, controlled phase III clinical study of the efficacy and safety of photodynamic therapy using porfimer sodium for injection as treatment for unresectable advanced perihilar cholangiocarcinoma

Treatment:
Chemotherapy: Systemic
Other

3C-13-1

Trial Leaders:
Afsaneh Barzi

A Phase III Double-blinded, Placebo Controlled Study of XilonixTM for Improving Survival in Metastatic Colorectal Cancer.

Treatment:
Immunotherapy

3C-13-6

Trial Leaders:
Jane Figueiredo

A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers.

Treatment:
(No treatments specified)

3C-13-8

Trial Leaders:
Anthony El-Khoueiry

A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer patients

Treatment:
Chemotherapy: Systemic

3C-14-1

Trial Leaders:
Heinz Josef Lenz

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Treatment:
Chemotherapy: Systemic

3C-15-2

Trial Leaders:
Heinz Josef Lenz

BOND-3: A Randomized, Double-blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared with Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer

Treatment:
Chemotherapy: Systemic

3G-15-1

Trial Leaders:
Syma Iqbal

Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma

Treatment:
Chemotherapy: Systemic

3G-15-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Treatment:
Immunotherapy

3GB-14-1

Trial Leaders:
Anthony El-Khoueiry

A phase II multicenter, single arm study of oral BGJ398 in adult patients with advanced or metastatic cholangiocarcinoma with FGFR2 gene fusions or other FGFR genetic alterations who failed or are intolerant to platinum-based chemotherapy

Treatment:
Chemotherapy: Systemic

3GB-15-1

Trial Leaders:
Anthony El-Khoueiry

A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder

Treatment:
Chemotherapy: Systemic

3L-12-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination with Ipilimumab in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects who are Naive to Systemic Therapy

Treatment:
Immunotherapy

3L-13-3

Trial Leaders:
Anthony El-Khoueiry

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Treatment:
Chemotherapy: Systemic

3L-14-1

Trial Leaders:
Michael Katz

Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes (A Comparison of Two Different Catheter Systems for DEB-TACE)

Treatment:
Other

3P-13-2

Trial Leaders:
Heinz Josef Lenz

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment:
Biological Response Modifier
Chemotherapy: Systemic

3P-13-3

Trial Leaders:
Heinz Josef Lenz

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Treatment:
Chemotherapy: Systemic

3R-12-2

Trial Leaders:
Afsaneh Barzi

Phase II Trial of Neoadjuvant Bevacizumab with Modified FOLFOX7 in Patients with Stage II and III Rectal Cancer.

Treatment:
Anti-Angiogenesis
Chemotherapy: Systemic
Immunomodulator

4B-14-2

Trial Leaders:
Hooman Djaladat

Prevention of parastomal hernia following radical cystectomy and ileal conduit using biologic mesh: Randomized Clinical Trial

Treatment:
Other

4B-14-5

Trial Leaders:
Sarmad Sadeghi

PHII-130 Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients with Advanced or Unresectable Urothelial Carcinoma of the Bladder

Treatment:
Chemotherapy: Systemic

4B-15-12

Trial Leaders:
Tanya Dorff

A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) versus Observation as Adjuvant Therapy in Patients with PD-L1-Selected, High-Risk Muscle-Invasive Bladder Cancer After Cystectomy

Treatment:
Immunotherapy

4B-15-14

Trial Leaders:
Siamak Daneshmand

A Phase lb, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects with Muscle-Invasive Transitional Cell Carcinoma of the Bladder

Treatment:
Chemotherapy: Local
Surgery

4B-15-3

Trial Leaders:
David Quinn

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer

Treatment:
Immunotherapy

4B-15-4

Trial Leaders:
Mihir Desai

Prospective Randomized Comparison Of Robotic Versus Open Radical Cystectomy

Treatment:
Surgery

4P-06-3

Trial Leaders:
Jacek Pinski

A Phase I/II Trial of Adjuvant Post-Prostatectomy 3-D Conformal Radiation Therapy, Hormonal Therapy, and Concurrent Docetaxel for High Risk Pathologic T2-T3N0 Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone
Radiation: External

4P-13-2

Trial Leaders:
E. Todd Schroeder

Exercise and Protein Supplementation for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy.

Treatment:
Other

4P-14-1

Trial Leaders:
Mitchell Gross

Phase 2 Trial of Phenelzine in Non-Metastatic Recurrent Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-4

Trial Leaders:
Tanya Dorff

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Treatment:
Chemotherapy: Systemic

4P-14-7

Trial Leaders:
Mike Nguyen

Phase II Randomized, Placebo-Controlled Trial of PROSTVAC? (PSA-TRICOM) in Patientswith Clinically Localized Prostate Cancer Undergoing Active Surveillance

Treatment:
Vaccine

4P-14-8

Trial Leaders:
Leslie Ballas

Phase I dose-escalation study of SBRT for adjuvant/salvage radiotherapy in prostate cancer

Treatment:
Radiation: Other

4P-15-3

Trial Leaders:
David Quinn

ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi- Center Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA(AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)

Treatment:
Hormone

4T-14-1

Trial Leaders:
Siamak Daneshmand

Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment For Testicular Seminoma with Isolated Retroperitoneal Disease (1-2cm)

Treatment:
Surgery

5C-11-2

Trial Leaders:
Lynda Roman

Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer.

Treatment:
Chemotherapy: Systemic

5GYN-15-1

Trial Leaders:
Koji Matsuo

A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb-003) in Combination with Carboplatin plus Paclitaxel or Carboplatin plus Pegylated Liposomal Doxorubicin (PLD) in Subjects with Low CA125 Platinum-Sensitive Ovarian Cancer

Treatment:
Chemotherapy: Systemic

5U-13-1

Trial Leaders:
Koji Matsuo

PhII-129 A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer

Treatment:
Chemotherapy: Systemic

6G-12-2

Trial Leaders:
Naveed Wagle

A Phase II Study of Rindopepimut/GM-CSF in Patients with Relapsed EGFRvIII-Positive Glioblastoma.

Treatment:
Anti-Angiogenesis
Vaccine

7H-13-2

Trial Leaders:
Barbara Gitlitz

A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination with VTX-2337 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Treatment:
Chemotherapy: Systemic
Immunotherapy

7H-15-1

Trial Leaders:
Jorge Nieva

A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy with the IRX-2 Regimen in Patients with Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity

Treatment:
Biological Response Modifier
Chemotherapy: Systemic
Immunotherapy

7H-15-2

Trial Leaders:
Jorge Nieva

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Treatment:
Chemotherapy: Systemic
Immunotherapy

7H-15-3

Trial Leaders:
Barbara Gitlitz

PhII-136 Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

Treatment:
Immunotherapy

9L-11-8

Trial Leaders:
Ann Mohrbacher

HLA-Mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High-Risk Acute Myeloid Leukemia.

Treatment:
Chemotherapy: Systemic
Other

9L-13-1

Trial Leaders:
Casey O'Connell

Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative Myeloproliferative Neoplasms (MPN)

Treatment:
(No treatments specified)

9L-13-2

Trial Leaders:
Casey O'Connell

Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia

Treatment:
Chemotherapy: Systemic

9L-14-3

Trial Leaders:
Kevin Kelly

A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif®) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

Treatment:
Chemotherapy: Systemic

9L-14-4

Trial Leaders:
Casey O'Connell

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Treatment:
Chemotherapy: Systemic

9L-14-7

Trial Leaders:
Akil Merchant

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To Or Relapsed after First-Line Treatment with or without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Treatment:
Chemotherapy: Systemic

9L-15-1

Trial Leaders:
Casey O'Connell

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Treatment:
Chemotherapy: Systemic

9L-15-3

Trial Leaders:
Kevin Kelly

A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

Treatment:
Immunotherapy

9L-15-5

Trial Leaders:
Akil Merchant

PhII-134, Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy

Treatment:
Immunomodulator

CTSU-A071102

Trial Leaders:
Naveed Wagle

A Phase II/III Randomized Trial Of Veliparib Or Placebo In Combination With Adjuvant Temozolomide In Newly Diagnosed Glioblastoma with Mgmt Promoter Hypermethylation

Treatment:
Chemotherapy: Systemic

CTSU-A081105

Trial Leaders:
Barbara Gitlitz

Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Treatment:
Chemotherapy: Systemic

CTSU-E1411

Trial Leaders:
Anil Tulpule

Intergroup Randomized Phase II Four Arm Study In Patients =/>60 with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab + Bendamustine Followed By Rituximab Consolidation (RB-R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV-R); Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB-LR); or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV-LR).

Treatment:
Chemotherapy: Systemic
Immunomodulator
Immunotherapy

CTSU-E2810

Trial Leaders:
David Quinn

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy.

Treatment:
Anti-Angiogenesis

CTSU-E4512

Trial Leaders:
Barbara Gitlitz

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Treatment:
Chemotherapy: Systemic

CTSU/A031201

Trial Leaders:
Amir Goldkorn

Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer

Treatment:
Chemotherapy: Systemic

ctsu/CALGB-A011202

Trial Leaders:
Heather R. Macdonald

A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (CT1-3 N1) who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy

Treatment:
Radiation: External
Surgery

CTSU/COG-NRG ARST1321

Trial Leaders:
James Hu

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib

Treatment:
Radiation: External

CTSU/E7208

Trial Leaders:
Heinz Josef Lenz

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Treatment:
Anti-Angiogenesis

ctsu/NSABP-51/RTOG1304

Trial Leaders:
Eugene Chung

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Treatment:
Radiation: External

CTSU/RTOG-1112

Trial Leaders:
Anthony El-Khoueiry

Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Treatment:
Chemotherapy: Systemic
Radiation: External

ctsu/RTOG0848

Trial Leaders:
Syma Iqbal

A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.

Treatment:
Chemotherapy: Systemic
Radiation: External

GOG-0225

Trial Leaders:
Huyen Q. Pham

Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Progression-Free Survival?

Treatment:
(No treatments specified)

GOG-9929

Trial Leaders:
Huyen Q. Pham

A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph Nodes.

Treatment:
Chemotherapy: Systemic
Immunotherapy
Radiation: External

NC-HEM-14-5

Trial Leaders:
Ilene Weitz

An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH).

Treatment:
(No treatments specified)

NC-HEM-14-6

Trial Leaders:
Howard Liebman

Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 (Anti-CD40L dAb) in Adult Subjects with Primary Immune Thrombocytopenia (ITP)

Treatment:
(No treatments specified)

NC-ONC-15-1

Trial Leaders:
James Hu

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Treatment:
Other

NRG-BN001

Trial Leaders:
Richard Jennelle

Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma

Treatment:
Chemotherapy: Systemic
Radiation: External

NRG-BR001

Trial Leaders:
Eugene Chung

A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases

Treatment:
Radiation: External

NRG-GU001

Trial Leaders:
Leslie Ballas

Randomized Phase II Trial of Postoperative Adjuvant IMRT following Cystectomy for pT3/pT4 Urothelial Bladder Cancer

Treatment:
Radiation: External

RTOG-0924

Trial Leaders:
Leslie Ballas

Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy In Unfavorable Intermediate Or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Treatment:
Radiation: External

RTOG-0926

Trial Leaders:
Leslie Ballas

A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical ReStaging

Treatment:
Chemotherapy: Systemic
Radiation: External

SWOG-S0820

Trial Leaders:
Syma Iqbal

A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).

Treatment:
Other

SWOG-S0931

Trial Leaders:
Tanya Dorff

EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

Treatment:
Anti-Angiogenesis

SWOG-S1011

Trial Leaders:
Siamak Daneshmand

A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.

Treatment:
Surgery

SWOG-S1200

Trial Leaders:
Christy Russell

Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer.

Treatment:
Other

SWOG-S1207

Trial Leaders:
Darcy Spicer

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1216

Trial Leaders:
David Quinn

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer.

Treatment:
Chemotherapy: Systemic
Hormone

SWOG-S1221

Trial Leaders:
Anthony El-Khoueiry

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer.

Treatment:
Chemotherapy: Systemic

SWOG-S1313

Trial Leaders:
Syma Iqbal

A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.

Treatment:
Chemotherapy: Systemic

SWOG-S1314

Trial Leaders:
Siamak Daneshmand

A Randomized Phase II Study of Co-Expression Extrapolation (Coxen) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Treatment:
Chemotherapy: Systemic

SWOG-S1318

Trial Leaders:
Akil Merchant

A Phase II Study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for Patients >/= 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL

Treatment:
Chemotherapy: Systemic

SWOG-S1505

Trial Leaders:
Afsaneh Barzi

A Randomized Phase II Study of Perioperative Mfolfirinox versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

Treatment:
Chemotherapy: Systemic

Phase I trials for all solid tumors:


0C-11-1

Trial Leaders:
Heinz Josef Lenz

Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction.

Treatment:
Chemotherapy: Systemic

0C-11-3

Trial Leaders:
Anthony El-Khoueiry

A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).

Treatment:
Anti-Angiogenesis

0C-12-3

Trial Leaders:
Heinz Josef Lenz

Phase I Trial of Oral 5-Fluoro-2’-Deoxycytidine With Oral Tetrahydrouridine in Patients With Advanced Solid Tumors.

Treatment:
Chemotherapy: Systemic

0C-13-1

Trial Leaders:
Anthony El-Khoueiry

An Open-Label, Parallel-Group, Multi-Center Phase I Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients with Advanced or Metastatic Solid Tumors and Mild or Moderate Hepatic Impairment.

Treatment:
Chemotherapy: Systemic

0C-13-6

Trial Leaders:
Heinz Josef Lenz

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 In Combination with Capecitabine in Patients with Advanced Solid Tumors

Treatment:
Chemotherapy: Systemic

0C-13-7

Trial Leaders:
Heinz Josef Lenz

A Phase 1b, Multi-Center, Non-Randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY 73-4506) in Combination with Cetuximab In Subjects with Locally Advanced or Metastatic Solid Tumors Who aren not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as A Standard Treatment

Treatment:
Chemotherapy: Systemic

0C-14-10

Trial Leaders:
Anthony El-Khoueiry

A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD5363 under Adaptable Dosing Schedules in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Local

0C-14-6

Trial Leaders:
David Quinn

A Phase I, Open-Label, Multi-Center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients with Advanced Solid Malignancies

Treatment:
Immunotherapy

0C-14-9

Trial Leaders:
Anthony El-Khoueiry

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD6738 in combination with Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients with Advanced Solid Malignancies

Treatment:
Chemotherapy: Systemic

0S-08-9

Trial Leaders:
Tanya Dorff

Short-Term Fasting Prior to Platinum-Based Chemotherapy: Feasibility and Impact on Toxicity.

Treatment:
Chemotherapy: Systemic

SWOG-S1221

Trial Leaders:
Anthony El-Khoueiry

Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib and Trametinib in Patients with BRAF Mutant Cancer.

Treatment:
Chemotherapy: Systemic

Trials which are NOT treatments of disease. Specimens or information may be collected:


0S-00-15

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer.


0S-00-16

Trial Leaders:
Heinz Josef Lenz

Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer.


0S-04-7

Trial Leaders:
Michael Press

USC Tumor and Tissue Bank.


0S-08-5

Trial Leaders:
Darcy Spicer

Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project.


0S-10-1

Trial Leaders:
Florence Wong

A Survey of Complementary and Alternative Medicine (CAM) Use and Interest to Participate in CAM Research Studies in a Comprehensive Cancer Center.


0S-11-3

Trial Leaders:
Charite Ricker

Intervention to Promote Uptake of Cancer Risk Counseling for Underserved Latinas.


0S-11-5

Trial Leaders:
Amir Goldkorn

Circulating Tumor Cell Collection from Cancer Patients.


0S-11-9

Trial Leaders:
Michael Wong

Proleukin Observational Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy.


0S-12-4

Trial Leaders:
Stephen Gruber

USC Norris Comprehensive Cancer Center - Cancer Genetics Registry.


0S-13-1

Trial Leaders:
Gregory Idos

USC Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing


0S-15-12

Trial Leaders:
Stephen Gruber

Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership with Patients.


0S-15-7

Trial Leaders:
Irene Woo

Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility-A pilot study,A Pilot Study


0S-15-9

Trial Leaders:
Heinz Josef Lenz

PhI-78, Patient-Derived Models Tissue Procurement Protocol For The National Cancer Institute (NCI)


0S-16-2

Trial Leaders:
Jorge Nieva

Accelerometry to Optimize and Monitor Human Performance in Cancer Chemotherapy Outpatients


0S-99-10

Trial Leaders:
Heinz Josef Lenz

Blood Collection in Patients with GI Cancer.


1B-11-1

Trial Leaders:
Julie Lang

Breast Cancer Blood Biorepository.


1B-12-4

Trial Leaders:
Marisa Perdomo

Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer.


1B-12-6

Trial Leaders:
Jaques Van Dam

Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study.


1B-12-9

Trial Leaders:
Darcy Spicer

An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with Her2 Positive (Her2+) Metastatic Breast Cancer.


1B-13-2

Trial Leaders:
Julie Lang

Core Biopsies of Breast Tumor Tissue Repository.


1B-13-8

Trial Leaders:
Linda Hovanessian

Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer.


1B-14-6

Trial Leaders:
Anna Wu

Changes in Intestinal Microbiota in Association with Chemotherapy Treatment


1B-15-3

Trial Leaders:
Alexandra Sleight

Supportive Care Needs Of Breast Cancer Survivors At LAC+USC: A Cross-Sectional Survey


2L-10-1

Trial Leaders:
Barbara Gitlitz

Addario Lung Cancer Medical Institute (ALCMI) Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network.


2L-14-1

Trial Leaders:
Barbara Gitlitz

Genomics of Young Lung Cancer Study


2L-15-1

Trial Leaders:
Christopher Lee

Biospecimen Banking and Biomarker Validation for Lung Cancer Early Detection in Cohort Receiving Low Dose Helical Computed Tomography Screening


2N-12-7

Trial Leaders:
Daniel Oh

DNA Methylation Markers for Detecting Cancer Cells in Malignant Pleural Effusion.


2O-13-1

Trial Leaders:
Barbara Gitlitz

Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer


3C-13-2

Trial Leaders:
Afsaneh Barzi

A Pilot Study of Monitoring Metastatic Colorectal Cancers with Liquid Biopsies.


3G-07-2

Trial Leaders:
Heinz Josef Lenz

Early Onset and Familial Gastric Cancer Registry.


3G-07-3

Trial Leaders:
Heinz Josef Lenz

Establishing Continuous Cell Lines and Xenografts from Adult Malignant Solid Tumors and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies.


3G-07-4

Trial Leaders:
Heinz Josef Lenz

Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers.


4B-13-1

Trial Leaders:
Siamak Daneshmand

4B-13-1 Cysview® Blue Light Cystoscopy Registry


4B-13-4

Trial Leaders:
Siamak Daneshmand

Evaluation of the UroVysion™ Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG for Primary High Grade Ta-T1 and CIS Urothelial Carcinoma of the Bladder


4B-15-10

Trial Leaders:
Siamak Daneshmand

A Prospective, Open, Comparative, within Patient Controlled Multicenter Phase 3 study of Blue Light Cystoscopy with Cysview and White Light Cystoscopy using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer In Patients with Bladder Cancer


4B-15-2

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection And Monitoring in Bladder Carcinoma


4B-15-5

Trial Leaders:
Andrew Weitz

Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness


4K-03-2

Trial Leaders:
Eila Skinner

Kidney Cancer Data and Specimen Collection Project.


4K-14-4

Trial Leaders:
Jacek Pinski

MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma


4P-01-2

Trial Leaders:
Eila Skinner

Prostate Cancer Prostatectomy Data and Specimen Collection Project.


4P-11-4

Trial Leaders:
Mitchell Gross

Multi-Dimensional Assessment of Circulating Tumor Cells in Patients Treated For Metastatic Prostate Cancer.


4P-12-3

Trial Leaders:
Alan Epstein

MDSC Clinical Assay for Cancer Detection and Monitoring in Prostate Cancer.


4P-14-6

Trial Leaders:
Mitchell Gross

Assessment of Novel Biomarkers in Patients with Metastatic Castration Resistant Prostate Cancer


5GYN-10-3

Trial Leaders:
Lynda Roman

Banking Tissues from Normal and Disease-Related Gynecologic Surgeries.


6CNS-07-1

Trial Leaders:
Thomas Chen

Establishment of USC CNS and Spine Tumor Bank.


9L-10-3

Trial Leaders:
Preet Chaudhary

Comprehensive Hematology Tissue Repository (BANK).


CTSU-A151216

Trial Leaders:
Barbara Gitlitz

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


NC-HEM-05-4

Trial Leaders:
Casey O'Connell

Hematology Database


NC-HEM-06-5

Trial Leaders:
Anil Tulpule

Retrospective Clinipathologic Analysis of HIV-Associated Hodgkin’s Disease.


NC-HEM-12-1

Trial Leaders:
Anil Tulpule

Inhibition of proteasomal degradation of Nrf2 to augment antioxidant responses in sickle cell anemia


SWOG-S1013

Trial Leaders:
Heinz Josef Lenz

A Prospective Study of Epidermal Growth Factor Receptor (HER-1/EGFR) Inhibitor-Induced Dermatologic Toxicity: Validation of the Functional Assessment of Cancer Therapy-EGFRI 18 (FACT-EGFRI 18) Questionnaire for EGFRI-Induced Skin Toxicities.